Bucillamine suppresses human Th1 cell development by a hydrogen peroxide-independent mechanism

Journal of Rheumatology

Volumn 27, Issue 4, 2000, Pages 851-858

  Morinobu, Akio ^a   Wang, Zhengyu ^a   Kumagai, Shunichi ^a  

^a KOBE UNIVERSITY   (Japan)

Author keywords

Bucillamine; Cytokines; D penicillamine; Disease modifying antirheumatic drug; Rheumatoid arthritis; Th1 Th2 cell

Indexed keywords

BUCILLAMINE; CATALASE; CD28 ANTIGEN; CD4 ANTIGEN; CD45 ANTIGEN; DRUG METABOLITE; GAMMA INTERFERON; HYDROGEN PEROXIDE; OKT 3; PENICILLAMINE; RECOMBINANT INTERLEUKIN 2;

ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG MECHANISM; FLOW CYTOMETRY; HUMAN; HUMAN CELL; INTERFERON PRODUCTION; LYMPHOCYTE COUNT; LYMPHOCYTE CULTURE; LYMPHOCYTE DIFFERENTIATION; MONONUCLEAR CELL; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; T LYMPHOCYTE SUBPOPULATION; TH1 CELL;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIGENS, CD45; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CD4-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CELLS, CULTURED; CYSTEINE; FLOW CYTOMETRY; HUMANS; HYDROGEN PEROXIDE; INTERFERON TYPE II; INTERLEUKIN-12; INTERLEUKIN-2; INTERLEUKIN-4; OXIDANTS; PENICILLAMINE; TH1 CELLS;

EID: 0034120919     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Miossec P, van der Berg W. Th1/Th2 cytokine balance in arthritis. Arthritis Rheum 1997;40:2105-15.
2. Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989;7:145-73.
3. Salgame P, Abrams JS, Clayberger C, et al. Differing lymphokine profiles of functional subsets of human CD4 and CD8 T cell clones. Science 1991;254:279-82.
4. Romagnani S. Lymphokine production by human T cells in disease states. Annu Rev Immunol 1994;12:227-57.
5. Simon AK, Seipelt E, Sieper J. Divergent T-cell cytokine patterns in inflammatory arthritis. Proc Natl Acad Sci USA 1994;91:8562-6.
6. Schulze KH, Lipsky PE, Kavanaugh AF, Davis LS, Elevated Th1- or Th0-like cytokine mRNA in peripheral circulation of patients with rheumatoid arthritis. Modulation by treatment with anti-ICAM-1 correlates with clinical benefit. J Immunol 1995;155:5029-37.
7. Dolhain RJEM, van der Heiden AN, ter Haar NT, Breedveld FC, Miltenburg AMM. Shift toward T lymphocytes with a T helper 1 cytokine-secretion profile in the joints of patients with rheumatoid arthritis. Arthritis Rheum 1996;39:1961-9.
8. Morita Y, Yamamura M, Kawashima M, et al. Flow cytometric single-cell analysis of cytokine production by CD4+ T cells in synovial tissue and peripheral blood from patients with rheumatoid arthritis. Arthritis Rheum 1998;41:1669-76.
9. Chomarat P, Vannier E, Dechanet J, et al. Balance of IL-1 receptor antagonist/IL-1b in rheumatoid synovium and its regulation by IL-4 and IL-10. J Immunol 1995;154:1432-9.
10. Walmsley M, Katsikis PD, Abney E, et al. Interleukin-10 inhibition of the progression of established collagen-induced arthritis. Arthritis Rheum 1996;39:495-503.
11. Joosten L, Lubberts E, Durenz P, et al. Role of interleukin-4 and interleukin-10 in murine collagen-induced arthritis: protective effect of interleukin-4 and interleukin-10 treatment on cartilage destruction. Arthritis Rheum 1997;40:249-60.
12. Delespesse G, Demeure CE, Yang LP, Oshima Y, Byun DG, Shu U. In vitro maturation of naive human CD4+ T lymphocyte into Th1, Th2 effectors. Int Arch Allergy Immunol 1997;113:153-6.
13. Sornasse T, Larenas PV, Davis KA, de Vries J, Yssel H. Differentiation and stability of T helper 1 and 2 cells derived from naive human neonatal CD4+ T cells, analyzed at the single-cell level. J Exp Med 1996;184:473-83.
14. Hayashi M, Matsunaga K, Okahara A, Mita S. Effect of bucillamine (SA96) on type II collagen induced arthritis in rats. J Rheumatol 1991;18:691-5.
15. Kashiwazaki S, Shiokawa Y. Bucillamine: a new immunomodulator. Int J Immunotherapy 1987;3:1-6.
16. Lipsky PE. Immunosuppression by D-penicillamine in vitro. Inhibition of human T lymphocyte proliferation by copper-or ceruloplasmin-dependent generation of hydrogen peroxide and protection by monocytes. J Clin Invest 1984;73:53-65.
17. Akamatsu T, Matsubara T, Saegusa Y, Mizuno K. Inhibition of mitogen-induced response of human peripheral blood mononuclear cells by bucillamine, a new antirheumatic sulfhydryl drug. Rheumatol Int 1994;13:297-201.
18. Matsubara T, Hirohata K. Suppression of human fibroblast proliferation by D-penicillamine and copper sulfate in vitro. Arthritis Rheum 1988;31:964-72.
19. Aono H, Hasunuma T, Fujisawa K, et al. Direct suppression of human synovial cell proliferation in vitro by salazosulfapyridine and bucillamine. J Rheumatol 1996;23:65-70.
20. Eguchi K, Kawakami A, Ida H, et al. Bucillamine inhibits T cell adhesion to human endothelial cells. J Rheumatol 1992;19:1045-50.
21. Hashimoto K, Lipsky PE. Immunosuppression by the disease modifying antirheumatic drug bucillamine: inhibition of human T lymphocyte function by bucillamine and its metabolites. J Rheumatol 1993;20:953-7.
22. Hirohata S, Lipsky PE. Comparative inhibitory effects of bucillamine and D-penicillamine on the function of human B cells and T cells. Arthritis Rheum 1994;37:942-50.
23. Martinez F, Coleman J. The effect of selected drugs, including chlorpromazine and non-steroidal anti-inflammatory agents, on polyclonal IgG synthesis and interleukin 1 production by human peripheral blood mononuclear cells in vitro. Clin Exp Immunol 1989;76:252-7.
24. Okamoto M, Sasano M, Goto M, et al. Suppressive effect of antirheumatic drugs on interleukin-1 beta release from human peripheral blood monocytes. Int J Immunopharmacol 1991;13:39-43.
25. Barrea P, Boerbooms AMTh, van de Putte LBA, van der Meer JWM. Effects of antirheumatic agents on cytokines. Semin Arthritis Rheum 1996;25:234-53.
26. Picker LJ, Singh MK, Zdraveski Z, et al. Direct demonstration of cytokine synthesis heterogeneity among human memory/effector T cells by flow cytometry. Blood 1995;86:1408-19.
27. Shu U, Demeure CE, Byun DG, Podlaski F, Stern AS, Delespesse G. Interleukin 12 exerts a differential effect on the maturation of neonatal and adult human CD45RO-CD4 T cells. J Clin Invest 1994;94:1352-8.
28. Matsuno M, Sugiyama E, Muraguchi A, et al. Pharmacological effects of SA98 (bucillamine) and its metabolites as immunomodulating drugs - the disulfide structure of SA-96 metabolites plays a critical role in the pharmacological action of the drug. Int J Immunopharmacol 1998;20:295-304.